Clinical Trials Logo

Clinical Trial Summary

Background. Brain metastases (BM) are the most common intracranial tumor and occur in 20-40% of all oncological patients. The most common primary cancer in brain metastases is lung cancer, followed by melanoma, breast cancer, renal cancer and colorectal cancer. The incidence of brain metastases has been increasing but the occurrence of brain metastases is still associated with high morbidity and poor prognosis. The main treatment methods are stereotactic radiosurgery (SRS), microsurgical resection and whole brain irradiation (WBRT). In contrast to microsurgical resection, Gamma Knife radiosurgery (GKRS) is a non-invasive neurosurgical method, which allows treatment in multimorbid patients with contraindications for surgery in general anesthesia. Furthermore, stereotactic radiosurgery is the only local treatment method for multiple disseminated and thereby non-resectable brain metastases. In general, microsurgical resection is considered the treatment of choice for BM exceeding >3 cm in diameter. However, since the establishment of the dose-staged technique, larger metastases can also be treated radiosurgically in selected patients. This novel method allows the application of high cumulative dose for the treatment of complex brain metastases. Aim. The aim of the study is to evaluate the clinical outcome in brain metastases patients with tumor volume between 8 and 20 ccm3. The clinical outcome will be compared between surgically and radiosurgically treated BM patients. Patients and methods. The investigators plan to conduct an explorative prospective study including about 50 radiosurgically and 50 surgically treated patients with brain metastases. If a patient fulfill study-relevant inclusion criteria at the time of BM diagnosis, the principle study investigator will offer both treatment options to the patient. Depending on patient's choice, he/she will be categorized either to surgical or to radiosurgical treatment group. For the outcome evaluation of the different treatment options, a comprehensive database will be established. The study participations will not interfere with any clincally indicated therapeutic decisions and the study participants will not be exposed to any additional risks since both treatments represent suitable therapy options.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04857905
Study type Interventional
Source Medical University of Vienna
Contact Josa Frischer, MD, PhD
Phone +43 1 40400 45510
Email [email protected]
Status Recruiting
Phase N/A
Start date July 1, 2020
Completion date December 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT02082587 - Toronto BNB Pilot Study N/A
Terminated NCT01551680 - A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases Phase 1
Terminated NCT00717275 - Study of Temozolomide to Treat Newly Diagnosed Brain Metastases Phase 2
Recruiting NCT03714243 - Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases N/A
Recruiting NCT04170777 - Perfexion Registration Using CBCT
Not yet recruiting NCT04474925 - Pre- Versus Post-operative SRS for Resectable Brain Metastases Phase 3
Not yet recruiting NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Recruiting NCT04582968 - Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases Phase 1/Phase 2
Recruiting NCT03027544 - Tomotherapy for Refractory Brain Metastases N/A
Completed NCT04178330 - Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases N/A
Terminated NCT02187822 - Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Phase 1
Recruiting NCT04246879 - MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases N/A
Recruiting NCT03653546 - First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System Metastases Phase 2/Phase 3
Recruiting NCT04410133 - Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases Phase 3
Recruiting NCT04040400 - Study of Intraoperative Radiotherapy for Patients With Large Brain Metastases Treated With Neurosurgical Resection N/A
Recruiting NCT04824079 - Keynatinib in Treated Patients With NSCLC and Brain Metastases Phase 2
Recruiting NCT02886585 - Pembrolizumab In Central Nervous System Metastases Phase 2
Completed NCT02654106 - Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases Phase 2
Completed NCT01480583 - GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases Phase 2
Completed NCT01252797 - Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002) Phase 1